Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Open Phase III Trial Testing Efficacy of Gemtuzumab Ozogamycin (MYLOTARG) Associated to Intensive Chemotherapy for Patients Aged Between 18-60 Years and Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk

NCT00860639 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT00860639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00860639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Open Phase III Trial Testing Efficacy of Gemtuzumab Ozogamycin (MYLOTARG) Associated to Intensive Chemotherapy for Patients Aged Between 18-60 Years and Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk
Lead sponsor
Nantes University Hospital
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2007
Completion date
September 26, 2016
Enrollment
327 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia